U.S., Oct. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07875179) titled 'IMPROVE-STEMI: pPCI Plus Low-dose r-SK in STEMI' on Sept. 20.
Brief Summary: This is a multicenter, prospective, pragmatic, randomized controlled trial (IMPROVE-STEMI) aiming to evaluate the efficacy and safety of intracoronary low-dose recombinant streptokinase combined with primary percutaneous coronary intervention (pPCI) in patients with acute ST-segment elevation myocardial infarction (STEMI).
A total of 3,300 patients will be enrolled, consisting of a core randomized study (300 patients, 1:1 ratio to pPCI + recombinant streptokinase vs. pPCI alone) and an extended observational study (3,000 patients receiving pPCI + recombina...